Stockscreener 앱 받기
2.18
5.22%
-0.12
시간 외 거래:
2.22
0.04
+1.83%
전일 마감가:
$2.30
열려 있는:
$2.31
하루 거래량:
785.98K
Relative Volume:
0.69
시가총액:
$393.17M
수익:
$109.16M
순이익/손실:
$-107.78M
주가수익비율:
-1.9705
EPS:
-1.1063
순현금흐름:
$-95.45M
1주 성능:
-1.36%
1개월 성능:
-6.84%
6개월 성능:
+250.20%
1년 성능:
+273.93%
1일 변동 폭
$2.18
$2.33
1주일 범위
$2.09
$2.39
52주 변동 폭
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
명칭
Century Therapeutics Inc
전화
215-981-4000
주소
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.18 | 414.82M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | TD Cowen | Buy |
| 2024-08-08 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 개시 | Chardan Capital Markets | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-05-23 | 개시 | H.C. Wainwright | Buy |
| 2022-05-12 | 개시 | William Blair | Mkt Perform |
| 2021-07-13 | 개시 | BofA Securities | Buy |
| 2021-07-13 | 개시 | JP Morgan | Overweight |
| 2021-07-13 | 개시 | Piper Sandler | Overweight |
모두보기
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com - Investing.com Australia
Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com - Investing.com India
Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding - Stock Titan
Tax-related share sale by Century Therapeutics (IPSC) SVP Carr - Stock Titan
Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting - Stock Titan
Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings - Stock Titan
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation - Yahoo Finance
Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options - Stock Titan
Director Daphne Quimi receives 74,000 stock options at Century Therapeutics (NASDAQ: IPSC) - Stock Titan
Century Therapeutics (IPSC) director receives grant of 74,000 stock options - Stock Titan
Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24 - Stock Titan
Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell - Stock Titan
Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate - Stock Titan
Insider sale notice for IPSC (NASDAQ: IPSC) — 2,584 shares planned; prior disposals listed - Stock Titan
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813 - Insider Monkey
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Century Therapeutics (IPSC) executive logs small automatic share sale for taxes - Stock Titan
Century Therapeutics (IPSC) SVP’s automatic 249-share sale covers RSU tax withholding - Stock Titan
Century Therapeutics (NASDAQ: IPSC) CEO has 463 shares withheld for RSU taxes - Stock Titan
Century Therapeutics, Inc. (IPSC) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IPSC) 2026-06-09 - Seeking Alpha
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Century Therapeutics Advances CNTY-813 Diabetes Cell Therapy - TipRanks
Century Therapeutics presents preclinical data on diabetes therapy By Investing.com - Investing.com Canada
Century Therapeutics presents preclinical data on diabetes therapy - Investing.com
Century Therapeutics (NASDAQ: IPSC) details CNTY-813 diabetes cell therapy data - Stock Titan
New CNTY-813 Preclinical Data Demonstrate Durable Glucose - GlobeNewswire
IPSC (NASDAQ: IPSC) Form 144: proposed sale of vested common shares - Stock Titan
Number of shareholders of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Century Therapeutics (IPSC) Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Advances - newsline.com
Century Therapeutics Price Target Announced at $8.00/Share by Mizuho - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Mizuho Initiates Century Therapeutics at Outperform - Moomoo
Century Therapeutics (IPSC) Inches Higher, Approaches Key Resistance LevelVWAP Deviation - newsline.com
This GE Aerospace analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Mizuho Initiates Century Therapeutics at Outperform With $8 Price Target - marketscreener.com
Century Therapeutics Initiated at Outperform by Mizuho - Moomoo
Mizuho initiates Century Therapeutics stock coverage at Outperform - Investing.com
Mizuho initiates Century Therapeutics stock coverage at Outperform By Investing.com - Investing.com Canada
Mizuho initiates coverage of Century Therapeutics (IPSC) with outperform recommendation - MSN
Century Therapeutics (IPSC) Holds Near Support After Modest DeclineChart Pattern Alerts - The Legal Advocate
Century Advances Diabetes Cell Therapy Toward Human Trials - MyChesCo
IPSC Stock Price, Quote & Chart | CENTURY THERAPEUTICS INC (NASDAQ:IPSC) - ChartMill
Century Therapeutics Q1 2026 Earnings: EPS Surpasses Estimates as Pipeline Progress ContinuesRising Community Picks - Newser
IPSC (NASDAQ: IPSC) resale supplement substitutes Point72 with SILV Fund - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), Century Therapeutics (IPSC) - The Globe and Mail
Century Therapeutics (IPSC) CEO has 31,172 shares withheld to cover RSU tax obligations - Stock Titan
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock - MSN
Century Therapeutics (IPSC) Stock: Slides -1.68%, Support at $2.22 2026-05-15Professional Trade Ideas - newser.com
Century Therapeutics Inc (IPSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Century Therapeutics Inc 주식 (IPSC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations |
Jun 12 '26 |
Sale |
2.23 |
1,654 |
3,692 |
505,094 |
1.27%
1.43%
자본화:
|
볼륨(24시간):